Abstract
Prevention of cervical cancer in HIV-positive women is possible through regular cervical cytological screening for early detection and a variety of effective treatment options for dysplasia. Women with HIV infection continue to have an increased rate of CIN, and cervical dysplasia appears to recur more frequently and progress more rapidly in severely immunocompromised women with high-risk type HPV infection. The Pap test is an effective screening tool, but high rates of recurrence in immunocompromised women reinforce the need for more frequent screening in HIV-positive women with a history of abnormal smears and CD4 counts less than 200. Health care providers should be aware of the latest recommendations for cervical dysplasia evaluation and should apply these in their care of HIV-infected women. Early detection, prompt treatment, and meticulous follow-up are essential in the prevention of cervical dysplasia, as well as the morbidity and mortality associated with cervical cancer in women with HIV.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
